David Nicholson: Developing New Treatments for Mental Illnesses
MAY 17, 2016
With a wide range of mental health issues needing advancements in treatment there is constant work being done to find new medications that can help the various patient populations.
C. David Nicholson, PhD, Chief R&D Officer for Allergan discussed some of their developmental works during the American Psychiatric Association's annual meeting in Atlanta. Nicholson cited one specific example of a new potential antidepressant which could be effective in a matter of hours rather than weeks as is the case with current medications available on the market.